Wockhardt receives US FDA approval for Olopatadine HCI

Olopatadine HCI, eye drop to treat ophthalmic allergies, is a generic version of Patanol

Wockhardt has received final approval from US FDA for its ANDA for 0.1 per cent ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1 per cent ophthalmic solution is a generic version of Patanol, marketed at a US by Alcon, a subsidiary of Novartis

The product will be manufactured at US FDA approved contract manufacturing organisation based in Montreal, Canada.